Philips Q4 earnings beat EPS but miss revenue; shares dip 2%, while its €10 M SEISMIC brain‑therapy partnership aims to pioneer minimally invasive neuromodulation for Parkinson’s, tremor, and epilepsy.
Philips named a Clarivate Top 100 Global Innovator for 13th consecutive year, proving its evidence‑based, regulatory‑compliant tech drives safer, cost‑efficient patient care worldwide.
Philips tops Clarivate’s 2026 Global Innovators list for the 13th year, proving that its $1.9 bn R&D drive delivers safe, evidence‑based devices that cut ICU staff needs, lower readmission rates and empower patients to manage care at home.
Philips spins off its Emergency Care division into Heartstream, boosting focus on AI‑driven diagnostics while preserving emergency‑care expertise and regulatory compliance.
Philips’ strong finances and AI‑driven imaging give a neutral “Hold” but modest upside—investors should weigh EU reimbursement shifts, tech rollout, and cost‑efficiency risks for long‑term value.
Royal Philips launches AI‑powered spectral CT and helium‑free 3‑T MRI, cutting scan time, dose, and operating costs while boosting diagnostic accuracy for faster, more efficient patient care.
Philips launches DeviceGuide, an AI‑powered tool that gives real‑time 3‑D device tracking to cut mitral valve repair complications, radiation, and procedure time by up to 26 %.